Completed PHASE1 INTERVENTIONAL 2-arm NCT01544881

Comparison of Technosphere Insulin Inhalation Powder & Subcutaneous Rapid-Acting Analog in Subjects With Type 1 Diabetes

A Phase 1, Single-center, Open-label, Randomized, Crossover Design Clinical Study in Subjects With Type 1 Diabetes Comparing Insulin Exposure & Response Following Inhalation of Technosphere Insulin Inhalation Powder Using the Gen2C Inhaler Vs Subcutaneous Rapid-Acting Analog

Sponsor: Mannkind Corporation

Conditions Type 1 Diabetes Mellitus

Interventions Rapid Acting Analog Technosphere Insulin Inhalation Powder

Updated 6 times since 2017 Last updated: Jan 24, 2013 Started: Mar 31, 2012 Primary completion: Sep 30, 2012 Completion: Jan 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Type 1 Diabetes Mellitus, this trial is completed. The trial is conducted by Mannkind Corporation and has accumulated 6 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Mar 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Mannkind Corporation

Data source: Mannkind Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chula Vista, United States